These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 9232213

  • 1. The effect of cholecystokinin tetrapeptide on respiratory resistance in healthy volunteers.
    Shlik J, Vasar V, Aluoja A, Kingisepp PH, Jagomägi K, Vasar E, Rägo L, Bradwejn J.
    Biol Psychiatry; 1997 Aug 01; 42(3):206-12. PubMed ID: 9232213
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers.
    Bradwejn J, LeGrand JM, Koszycki D, Bates JH, Bourin M.
    Am J Psychiatry; 1998 Feb 01; 155(2):280-2. PubMed ID: 9464212
    [Abstract] [Full Text] [Related]

  • 4. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings.
    Bradwejn J, Koszycki D, Shriqui C.
    Arch Gen Psychiatry; 1991 Jul 01; 48(7):603-10. PubMed ID: 2069490
    [Abstract] [Full Text] [Related]

  • 5. Effects of low-dose cholecystokinin on respiratory function in healthy volunteers.
    Schruers K, Caycedo N, Overbeek T, Büchold H, Bourin M, Griez E.
    Eur Neuropsychopharmacol; 2000 Sep 01; 10(5):419-21. PubMed ID: 10974616
    [Abstract] [Full Text] [Related]

  • 6. Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers.
    Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A.
    Biol Psychiatry; 1995 Dec 01; 38(11):742-6. PubMed ID: 8580227
    [Abstract] [Full Text] [Related]

  • 7. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study.
    Zwanzger P, Eser D, Aicher S, Schüle C, Baghai TC, Padberg F, Ella R, Möller HJ, Rupprecht R.
    Neuropsychopharmacology; 2003 May 01; 28(5):979-84. PubMed ID: 12700707
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In healthy volunteers responses to challenge with cholecystokinin tetrapeptide differ between administration during REM and delta sleep.
    Kronenberg G, Schredl M, Fiedler K, Heuser I.
    Depress Anxiety; 2001 May 01; 14(2):141-4. PubMed ID: 11668667
    [Abstract] [Full Text] [Related]

  • 10. A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder.
    Bradwejn J, Koszycki D, Annable L, Couëtoux du Tertre A, Reines S, Karkanias C.
    Biol Psychiatry; 1992 Nov 15; 32(10):903-12. PubMed ID: 1467375
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The effect of 6-week treatment with escitalopram on CCK-4 challenge: a placebo-controlled study in CCK-4-sensitive healthy volunteers.
    Tõru I, Maron E, Raag M, Vasar V, Nutt DJ, Shlik J.
    Eur Neuropsychopharmacol; 2013 Jul 15; 23(7):645-52. PubMed ID: 22939006
    [Abstract] [Full Text] [Related]

  • 14. Dose ranging study of the effects of cholecystokinin in healthy volunteers.
    Bradwejn J, Koszycki D, Bourin M.
    J Psychiatry Neurosci; 1991 Jul 15; 16(2):91-5. PubMed ID: 1911739
    [Abstract] [Full Text] [Related]

  • 15. Acute effects of cholecystokinin tetrapeptide on brain stem auditory evoked potentials in healthy volunteers.
    Gunnarsson T, Mahoney C, Shlik J, Bradwejn J, Knott V.
    Pharmacopsychiatry; 2003 Sep 15; 36(5):181-6. PubMed ID: 14571352
    [Abstract] [Full Text] [Related]

  • 16. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder.
    Ströhle A, Holsboer F, Rupprecht R.
    Neuropsychopharmacology; 2000 Mar 15; 22(3):251-6. PubMed ID: 10693152
    [Abstract] [Full Text] [Related]

  • 17. Distinct panicogenic activity of sodium lactate and cholecystokinin tetrapeptide in patients with panic disorder.
    Plag J, Gaudlitz K, Zschucke E, Yassouridis A, Pyrkosch L, Wittmann A, Holsboer F, Ströhle A.
    Curr Pharm Des; 2012 Mar 15; 18(35):5619-26. PubMed ID: 22632477
    [Abstract] [Full Text] [Related]

  • 18. Effect of aging on cholecystokinin-induced panic.
    Flint AJ, Koszycki D, Vaccarino FJ, Cadieux A, Boulenger JP, Bradwejn J.
    Am J Psychiatry; 1998 Feb 15; 155(2):283-5. PubMed ID: 9464213
    [Abstract] [Full Text] [Related]

  • 19. Effects of flumazenil on cholecystokinin-tetrapeptide-induced panic symptoms in healthy volunteers.
    Bradwejn J, Koszycki D, Couëtoux du Tertre A, Paradis M, Bourin M.
    Psychopharmacology (Berl); 1994 Mar 15; 114(2):257-61. PubMed ID: 7838917
    [Abstract] [Full Text] [Related]

  • 20. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder.
    Bradwejn J, Koszycki D, Meterissian G.
    Can J Psychiatry; 1990 Feb 15; 35(1):83-5. PubMed ID: 2180549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.